Assessment of the Effects of Postbiotic Supplementation with Lactobacillus rhamnosus CRL 1505 and Lactobacillus acidophilus (Johnsonii) La1, with a Focus on Interferon-Beta and Interleukin 6 ; Impact on Upper Respiratory Tract Infection Incidence.

It Is a Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Assessment of the Effects of Postbiotic Supplementation with Lactobacillus rhamnosus CRL 1505 and Lactobacillus acidophilus (Johnsonii) La1, with a Focus on Interferon-Beta and Interleukin 6 ; Impact on Upper Respiratory Tract Infection Incidence

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100119003106N46

Enrollment

150

Registered

2024-04-02

Start date

2024-03-10

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of postbiotic supplementation on upper respiratory tract infection with a focus on beta interferon and interleukin 6.. Acute upper respiratory infection, unspecifiedUpper respiratory:disease, acuteinfection NOS

Interventions

Intervention 1: Intervention group: All individuals receive a capsule of postbiotic that is prescribed after breakfast for a duration of 12 weeks. Intervention 2: Control group: All individuals recei

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adult men and women aged between 18 and 65 years who have a thorough comprehension of the potential risks and benefits. They are required to sign informed consent forms before participating.

Exclusion criteria

Exclusion criteria: Unwillingness to continue or participate in the study Diagnosis of immunodeficiency due to any diagnosed chronic disease Gastrointestinal ulcer Liver and kidney dysfunction Human immunodeficiency virus Autoimmune disorders Malignancy or any history of malignancy Any diagnosis of respiratory diseases with cold or flulike symptoms Severe diseases such as asthma and severe allergies Pregnancy, breastfeeding Drug or alcohol addiction Taking any immunosuppressants or immunomodulators

Design outcomes

Primary

Measure	Time frame
Interferon Beta. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Interleukin-6. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Assessment of the health of the upper respiratory system. Timepoint: Every day. Method of measurement: Wisconsin Upper Respiratory Symptom Survey (WURSS).;Complete blood count. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Band cells. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Neutrophil-to-lymphocyte ratio (NLR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Serum ferritin. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Plasmacytoid dendritic cells (CD 86, HLD-DR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Flow cytometry.	—

Measure

Time frame

Interferon Beta. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Interleukin-6. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: ELISA.;Assessment of the health of the upper respiratory system. Timepoint: Every day. Method of measurement: Wisconsin Upper Respiratory Symptom Survey (WURSS).;Complete blood count. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Band cells. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Neutrophil-to-lymphocyte ratio (NLR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Erythrocyte sedimentation rate (ESR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Serum ferritin. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Blood sample analysis.;Plasmacytoid dendritic cells (CD 86, HLD-DR). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Flow cytometry.

—

Secondary

Measure	Time frame
Quality of life assessment. Timepoint: Weekly. Method of measurement: Quality of life questionnaire (SF-36).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Zahra Behboodi

Islamic Azad University

Nazaninbehboodii@icloud.com+98 21 2631 5739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026